Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology